MedTrace Logo

A Pharmacokinetics Study of Intravenous Ascorbic Acid

NCT02534753 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2016-03-23

No results posted yet for this study

Summary

This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.

Conditions

  • Pharmacokinetics

Interventions

DRUG

Ascor L 500® (Ascorbic Acid Injection, USP)

A sterile, solution containing 500 mg ascorbic acid per mL

Sponsors & Collaborators

  • McGuff Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Damon P Jones, BS/MBA · McGuff Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2015-11-30
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02534753 on ClinicalTrials.gov